Insider Trading April 1, 2026

Tesla Director Disposes of $9.27M in Shares, Exercises Options for 40,000 Shares

Kathleen Wilson-Thompson sold 20,008 Tesla shares and exercised options the same day as mixed analyst views on deliveries and valuations persist

By Jordan Park TSLA
Tesla Director Disposes of $9.27M in Shares, Exercises Options for 40,000 Shares
TSLA

Tesla director Kathleen Wilson-Thompson sold 20,008 shares on March 30, 2026 for roughly $9.27 million and exercised options to acquire 40,000 additional shares at $14.99 each. The transactions leave her with 47,748 shares directly owned. The moves occur amid divergent analyst price targets and commentary on deliveries and regional demand.

Key Points

  • Tesla director Kathleen Wilson-Thompson sold 20,008 shares on March 30, 2026, raising roughly $9.27 million; she also exercised options for 40,000 shares at $14.99 each.
  • Tesla shares trade at $381.31 and carry a P/E ratio of 352; InvestingPro analysis cited in filings indicates the stock is overvalued relative to its Fair Value estimate.
  • Analysts have divergent views with price targets ranging from $24.86 to $600 and differing delivery estimates for Q1 2026, reflecting mixed sentiment across the automotive and equity markets.

Insider transaction details

Kathleen Wilson-Thompson, a director at Tesla, Inc. (NASDAQ:TSLA), executed a sale of 20,008 shares of common stock on March 30, 2026, generating approximately $9.27 million in proceeds. The sale prices recorded for the transactions ranged from $352.833 to $366.855 per share.

On the same day she completed the sale, Wilson-Thompson also exercised stock options that resulted in the acquisition of 40,000 shares of Tesla common stock at an exercise price of $14.99 per share, for a total cost of $599,600. After these combined transactions, she directly holds 47,748 shares of Tesla.


Market context provided in the filings

At the time of reporting, Tesla shares trade at $381.31. InvestingPro analysis cited in the filing indicates the shares are overvalued relative to its Fair Value estimate. The company’s valuation metrics show a price-to-earnings ratio of 352.


Analyst updates referenced alongside the insider activity

The company has seen several recent analyst actions. Canaccord Genuity lowered its price target to $420 from $520 while maintaining a Buy rating, citing sluggish performance in China and weak conditions in the U.S. and Europe. GLJ Research reiterated a Sell rating with a $24.86 price target and projects Tesla will deliver 368,478 vehicles in Q1 2026, a figure slightly above Wall Street’s consensus of 365,645.

RBC Capital maintained an Outperform rating with a $500 price target, estimating deliveries of 367,000 vehicles, which is slightly below the Visible Alpha consensus of 369,000. Wedbush reiterated an Outperform rating with a $600 price target and also speculated on the potential for a merger between Tesla and SpaceX by 2027.


Other notable mention

The filings and coverage also note an unusual diplomatic appearance: Elon Musk participated in a call with President Trump and Prime Minister Modi during a wartime crisis, an instance described as notable because it involved a private citizen in diplomatic communications.


Further research

For investors seeking a deeper review of Tesla’s valuation and financial profile, a comprehensive Pro Research Report is available for TSLA and for more than 1,400 other U.S. equities.

Risks

  • Valuation risk: InvestingPro’s analysis indicates the shares are overvalued compared to its Fair Value estimate, which is a risk for equity investors in the automotive and EV sectors.
  • Demand and delivery uncertainties: Analyst notes cite sluggish performance in China and weaker conditions in the U.S. and Europe, and delivery estimates for Q1 2026 vary, presenting execution risk for automotive industry expectations.
  • Market reaction to corporate and geopolitical actions: Speculation around strategic moves such as a potential merger and unusual diplomatic engagements by company leadership could influence investor sentiment and volatility in markets connected to the company.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026